| __timestamp | Ionis Pharmaceuticals, Inc. | Mesoblast Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 20140000 | 54170000 |
| Thursday, January 1, 2015 | 37173000 | 65378000 |
| Friday, January 1, 2016 | 48616000 | 52263000 |
| Sunday, January 1, 2017 | 108488000 | 35072000 |
| Monday, January 1, 2018 | 244622000 | 27415000 |
| Tuesday, January 1, 2019 | 287000000 | 36983000 |
| Wednesday, January 1, 2020 | 354000000 | 50918000 |
| Friday, January 1, 2021 | 186000000 | 63586000 |
| Saturday, January 1, 2022 | 151000000 | 57967000 |
| Sunday, January 1, 2023 | 232600000 | 53107000 |
| Monday, January 1, 2024 | 267474000 | 23626000 |
In pursuit of knowledge
In the competitive world of biotechnology, managing costs is crucial for success. Ionis Pharmaceuticals, Inc. and Mesoblast Limited, two prominent players, have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023. Ionis Pharmaceuticals experienced a dramatic increase in SG&A expenses, peaking in 2020 with a staggering 1,660% rise from 2014. This surge reflects their aggressive expansion and investment in research and development. However, post-2020, Ionis managed to reduce these costs by 47% by 2022, indicating a strategic shift towards efficiency.
Conversely, Mesoblast Limited maintained a more stable SG&A expense pattern, with a modest 21% increase over the same period. This stability suggests a conservative approach, focusing on sustainable growth. The data for 2024 is incomplete, highlighting the dynamic nature of financial forecasting in the biotech industry.
Cost Management Insights: SG&A Expenses for Sanofi and Mesoblast Limited
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Bio-Techne Corporation and Mesoblast Limited
Comparing SG&A Expenses: Walgreens Boots Alliance, Inc. vs Ionis Pharmaceuticals, Inc. Trends and Insights
Ionis Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs Xencor, Inc.
Operational Costs Compared: SG&A Analysis of Arrowhead Pharmaceuticals, Inc. and Mesoblast Limited
Operational Costs Compared: SG&A Analysis of Ligand Pharmaceuticals Incorporated and Mesoblast Limited
Mesoblast Limited vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Mesoblast Limited and BioCryst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Mesoblast Limited vs Evotec SE: SG&A Expense Trends